The landscape of diabetes management is rapidly changing , with the emergence of dual GIP and GLP-1 receptor agonists. Both Tirzepatide and Retatrutide represent important advancements; Tirzepatid already https://deweylvtt070721.blogofoto.com/74830196/tirzepatid-retatrutide-a-emerging-metabolic-health-partnership